** Shares of medical device maker DexCom DXCM.O rise 1.93% to $67.21

** Evercore ISI raises PT to $90 and upgrades rating to "outperform"

** Brokerage says DXCM could benefit as U.S. health programmes move toward covering glucose monitors for more patients with Type 2 diabetes who do not use insulin

** Says a clinical study testing DXCM's glucose monitor in these patients, due in 2Q26, could support Medicare coverage in late 2026, giving access to about 12 million patients; commercial insurers may follow

** Brokerage sees faster customer growth from 2028 helped by the roll out of co's new 15-day glucose sensor

** Expects double-digit revenue growth through 2028

** DXCM shares were down over 14% in 2025

(Reporting by Kunal Das in Bengaluru)

((Kunal.Das2@thomsonreuters.com;))